American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

David C Shonka Jr¹, Alan Ho², Ashish V Chintakuntlawar³, Jessica L Geiger⁴, Jong C Park⁵, Nagashree Seetharamu⁶, Sina Jasim⁷, Amr H Abdelhamid Ahmed⁸, Keith C Bible³, Marcia S Brose⁹, Maria E Cabanillas¹⁰, Kirsten Dabekaussen¹¹, Louise Davies¹², Dora Dias-Santagata¹³, James A Fagin¹⁴, William C Faquin¹³, Ronald A Ghossein¹⁵, Raj K Gopal⁵, Akira Miyauchi¹⁶, Yuri E Nikiforov¹⁷, Matthew D Ringel¹⁸, Bruce Robinson¹⁹, Mabel M Ryder²⁰, Eric J Sherman²¹, Peter M Sadow¹³, Jennifer J Shin²², Brendan C Stack Jr²³, R Michael Tuttle¹⁴, Lori J Wirth⁵, Mark E Zafereo Jr²⁴, Gregory W Randolph⁸

Affiliations

¹ Department of Otolaryngology - Head and Neck Surgery, University of Virginia, Charlottesville, Virginia, USA.
² Department of Hematology and Medical Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
³ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
⁵ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ Division of Hematology-Oncology, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, New York, USA.
⁷ Division of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, USA.
⁸ Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
⁹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁰ Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
¹¹ Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹² Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
¹³ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁴ Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁵ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁶ Department of Surgery, Kuma Hospital, Kobe, Japan.
¹⁷ Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
¹⁸ Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, Columbus, Ohio, USA.
¹⁹ Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
²⁰ Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
²¹ Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²² Department of Otolaryngology - Head and Neck Surgery, Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA.
²³ Department of Otolaryngology - Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
²⁴ Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

PMID: 35274388
PMCID: PMC9332138
DOI: 10.1002/hed.27025

Review

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

David C Shonka Jr et al. Head Neck. 2022 Jun.

. 2022 Jun;44(6):1277-1300.

doi: 10.1002/hed.27025. Epub 2022 Mar 11.

Authors

Affiliations

¹ Department of Otolaryngology - Head and Neck Surgery, University of Virginia, Charlottesville, Virginia, USA.
² Department of Hematology and Medical Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
³ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
⁵ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ Division of Hematology-Oncology, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, New York, USA.
⁷ Division of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, USA.
⁸ Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
⁹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁰ Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
¹¹ Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹² Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
¹³ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁴ Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁵ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁶ Department of Surgery, Kuma Hospital, Kobe, Japan.
¹⁷ Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
¹⁸ Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, Columbus, Ohio, USA.
¹⁹ Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
²⁰ Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
²¹ Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²² Department of Otolaryngology - Head and Neck Surgery, Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA.
²³ Department of Otolaryngology - Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
²⁴ Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

PMID: 35274388
PMCID: PMC9332138
DOI: 10.1002/hed.27025

Abstract

Background: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.

Methods: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.

Results: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.

Conclusions: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

Keywords: advanced thyroid cancer; consensus statement; molecular testing; systemic therapy; targeted treatment.

PubMed Disclaimer

Figures

**FIGURE 1**
Somatic mutational testing of advanced DTC

**FIGURE 2**
Somatic mutational testing of ATC

See this image and copyright information in PMC

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
1. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. - PubMed
1. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67(3):501–508. - PubMed
1. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. - PubMed
1. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P01 CA240239/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Affiliations

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical